P/E ratio for Roche (ROG.SW)

P/E ratio history for Roche from 2001 to 2022

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	11.0	-35.03%	🇺🇸 USA
Merck MRK	55.0	225.34%	🇺🇸 USA
Pfizer PFE	13.7	-18.77%	🇺🇸 USA
Sanofi SNY	15.2	-9.91%	🇫🇷 France
Novartis NVS	28.0	65.36%	🇨🇭 Switzerland
GlaxoSmithKline GSK	9.72	-42.54%	🇬🇧 UK
Abbott Laboratories ABT	39.5	133.90%	🇺🇸 USA
Amgen AMGN	20.8	22.90%	🇺🇸 USA
Becton Dickinson BDX	40.4	138.86%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.